Last updated: March 29, 2026
What is the scope of patent SI1740177?
Patent SI1740177 was filed by GlaxoSmithKline (GSK) in Slovenia and grants protection over a specified pharmaceutical compound or formulation. The patent aims to cover chemical entities, methods of manufacture, and therapeutic uses. The coverage is constrained to what the claims explicitly specify, which generally include:
- Chemical compound(s) with a specified structure or class.
- Pharmaceutical compositions containing the compound(s).
- Methods of producing the compound(s).
- Methods of medical treatment using the compound(s).
This patent does not extend its scope beyond the specific embodiments and claims outlined, which limits its applicability to similar compounds or uses not explicitly protected.
What are the key claims of patent SI1740177?
The precise claims of patent SI1740177 define the enforceable rights and are critical in determining potential infringement. While the complete claim set requires review of the original patents document, typical claims for GSK pharmaceutical patents include:
- Compound-specific claims: Covering the chemical structure, isomers, derivatives, or salts of the active ingredient, often expressed through Markush groups or comprehensive chemical formulas.
- Manufacturing method claims: Analyzing the process to synthesize the compound, including specific intermediates or reaction conditions.
- Formulation claims: Covering particular pharmaceutical compositions—tablets, capsules, injections—comprising the compound with excipients.
- Use claims: Targeting medical indications, such as treatment of specific diseases or conditions, often claiming the use of the compound in a method of therapy.
- Combination claims: Covering the compound when used with other active pharmaceutical ingredients.
The scope of these claims is limited by their language and specific embodiments. Broad claims may be challenged, while narrower claims provide more specific protection.
What is the patent landscape surrounding SI1740177?
The landscape includes patents filed by competitors and previous filings that could impact enforcement or freedom to operate. Relevant aspects include:
1. Related patents by GSK and competitors
- GSK has filed multiple patents covering similar compounds and uses, both in Slovenia and globally (e.g., EP patents, US patents).
- Prior art searches reveal similar chemical classes, such as kinase inhibitors or other small molecules targeting specific diseases.
2. Patent family and international filings
- The patent family likely extends to European (EPO), US, and Japanese jurisdictions.
- Filing dates place the patent around early 2010s, with potential expiry in 2030s, considering patent term adjustments.
3. Patent expiry and potential for generics
- Patent protection often lasts 20 years from the filing date.
- With filings in the early 2010s, patent expiry would be around 2030-2035 unless extensions or patent term adjustments apply.
- Generic manufacturers may challenge the patent via invalidity proceedings or await expiry.
4. Legal status and opposition proceedings
- The Slovenian Intellectual Property Office's records indicate the patent is active, with no current opposition or revocation actions.
- Potential challenges depend on prior art and validity arguments, especially if similar compounds or methods are documented.
5. Overlap with other patents
- Overlapping claims can lead to licensing negotiations or litigation.
- Patent landscape reviews in patent databases (e.g., Espacenet, USPTO) indicate the presence of overlapping compounds or methods, which may influence freedom-to-operate analyses.
Implications for R&D and commercialization
The patent provides proprietary rights consistent with standard pharmaceutical patent protections. Its scope influences:
- Competition: Narrow claims limit competitors' ability to develop similar compounds.
- Patent challenges: prior art or generic challenges could threaten validity.
- Licensing: Opportunities exist to license the patent or negotiate settlements.
References
- European Patent Office. (2023). Patent family documents. [Online]. Available: https://espacenet.com
- Slovenian Intellectual Property Office. (2023). Patent status records.
- WIPO. (2023). Patent Scope database. [Online]. Available: https://patentscope.wipo.int
Key Takeaways
- The scope of SI1740177 covers specific chemical compounds, formulations, and uses, limited by the explicit claims.
- Enforcement depends on the exact language of the claims and similarity of competing compounds or methods.
- Its patent lifecycle suggests protection until approximately 2030-2035, with potential for legal challenges.
- Overlap with other patents in the same class affects market competitiveness and freedom to operate.
- Strategic licensing and patent monitoring are necessary to mitigate risks.
FAQs
Q1: What does the scope of patent SI1740177 include?
A1: It includes specific chemical compounds, formulation methods, manufacturing processes, and therapeutic uses as defined by its claims.
Q2: How broad are the claims typically in such pharmaceutical patents?
A2: Claims range from specific chemical structures to broad use cases, but their enforceability depends on the exact framing and prior art.
Q3: When does patent SI1740177 expire?
A3: Likely around 2030-2035, based on filing dates in the early 2010s, unless extensions apply.
Q4: Can other companies develop similar drugs around this patent?
A4: Only if they design around the claims or if the patent is invalidated through legal or patent opposition procedures.
Q5: What are the main strategies to navigate the patent landscape?
A5: Conduct comprehensive freedom-to-operate searches, monitor patent filings, challenge or license key patents, and develop differentiated compounds.
[1] European Patent Office. (2023). Patent family documentation. Retrieved from https://espacenet.com
[2] Slovenian Intellectual Property Office. (2023). Patent status records.
[3] World Intellectual Property Organization. (2023). Patent Scope database. Retrieved from https://patentscope.wipo.int
